title: Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
abstract: A 6.4-fold cis-diamminedichloroplatinum(II) (CDDP) resistant human small cell lung carcinoma cell line (GLC4-CDDP) was developed to study acquired CDDP resistance in vitro. Compared to the sensitive cell line (GLC4), the GLC4-CDDP showed an increase in doubling time and a decrease in cloning efficiency, cellular size, double minutes per cell, cellular protein, and nuclear protein content. While a complete cross-resistance for tetraplatin and a partial cross-resistance for doxorubicin, melphalan, cadmium chloride, carboplatin, and cis-dichloro-trans-dihydroxo-cis-bis(isoprolylamine)platinum (IV) (resistance factor, respectively,4.0,5.8,2.1,1.5,2.9) was found, no cross-resistance for vincristine was found. In the GLC4-CDDP line in comparison to the GLC4 line, glutathione and total amount of sulfhydryl compounds was significantly increased, while glutathione S-transferase and glutathione reductase was the same. The platinum content in cells and nuclei was lower in the resistant line, but after correction for cellular protein or volume no difference was found. The amount of platinum bound to DNA was significantly lower in the GLC4-CDDP line. After a 1-h incubation with CDDP, the amount of Pt-GG adducts was the same and the amount of interstrand cross-links was reduced in the GLC4-CDDP line as compared to GLC4. In conclusion, in the GLC4-CDDP line the phenotype and genotype are changed and various mechanisms, such as decreased Pt-DNA binding, elevated glutathione, and reduced interstrand cross-links, play a role in the development of the CDDP resistance.
authors.affiliation: Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
authors.forename: G A
authors.initials: GA
authors.lastname: Hospers
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
authors.forename: B
authors.initials: B
authors.lastname: de Jong
authors.forename: L
authors.initials: L
authors.lastname: de Ley
authors.forename: D R
authors.initials: DR
authors.lastname: Uges
authors.forename: A M
authors.initials: AM
authors.lastname: Fichtinger-Schepman
authors.forename: R J
authors.initials: RJ
authors.lastname: Scheper
authors.forename: E G
authors.initials: EG
authors.lastname: de Vries
mesh_terms: D000596:Amino Acids / Q000032:analysis; D018288:Carcinoma, Small Cell / Q000032:analysis / Q000235:genetics / Q000473:pathology*; D002460:Cell Line; D002945:Cisplatin / Q000378:metabolism / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D004249:DNA Damage; D004351:Drug Resistance; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007621:Karyotyping; D008175:Lung Neoplasms / Q000032:analysis / Q000235:genetics / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000596:Amino Acids; D004247:DNA; D005978:Glutathione; D002945:Cisplatin